RLMD: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on Relmada Therapeutics with a buy rating and a price target of $12
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.